In a report released yesterday, Danielle Brill from Raymond James assigned a Hold rating to Global Blood Therapeutics (GBT). The company’s shares closed last Wednesday at $49.19.
According to TipRanks.com, Brill is a 4-star analyst with an average return of 17.2% and a 54.8% success rate. Brill covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Sarepta Therapeutics, and SAGE Therapeutics.
Currently, the analyst consensus on Global Blood Therapeutics is a Moderate Buy with an average price target of $74.29, a 53.9% upside from current levels. In a report released today, William Blair also downgraded the stock to Hold.
See today’s analyst top recommended stocks >>
The company has a one-year high of $83.69 and a one-year low of $36.49. Currently, Global Blood Therapeutics has an average volume of 1.11M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.
